Opinion|Videos|December 7, 2023
Treatment Options for KRASG12C Mutated NSCLC
Author(s)Narjust Florez, MD
Dr Narjust Florez outlines FDA-approved firstline therapy options for KRAS G12C mutated non-small cell lung cancer, and notes most patients progress and require second line targeted therapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
3
Trotabresib Plus CRT Fails to Improve PFS in Newly Diagnosed Glioblastoma
4
Can AI Fix Clinical Trial Access in Oncology? Dr. Arturo Loaiza-Bonilla Built the Answer With the Data to Back It.
5